3933 Stock Overview
The United Laboratories International Holdings Limited, an investment holding company, engages in the research, development, manufacture, distribution, and sale of pharmaceutical products.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
My Notes
NewNotes are coming soon
The United Laboratories International Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$5.10 |
| 52 Week High | HK$5.48 |
| 52 Week Low | HK$3.17 |
| Beta | 0.28 |
| 1 Month Change | 10.87% |
| 3 Month Change | 50.89% |
| 1 Year Change | 15.91% |
| 3 Year Change | -0.58% |
| 5 Year Change | -27.66% |
| Change since IPO | 41.27% |
Recent News & Updates
United Laboratories International Holdings (HKG:3933) Has A Rock Solid Balance Sheet
Dec 23
Are Investors Undervaluing The United Laboratories International Holdings Limited (HKG:3933) By 47%?
Oct 19Recent updates
United Laboratories International Holdings (HKG:3933) Has A Rock Solid Balance Sheet
Dec 23Are Investors Undervaluing The United Laboratories International Holdings Limited (HKG:3933) By 47%?
Oct 19Is United Laboratories International Holdings (HKG:3933) Using Too Much Debt?
Aug 30Is The United Laboratories International Holdings Limited (HKG:3933) A Smart Pick For Income Investors?
Mar 08The United Laboratories International Holdings (HKG:3933) Share Price Is Up 108% And Shareholders Are Boasting About It
Feb 18
The United Laboratories International Holdings Limited's (HKG:3933) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
Feb 03Did The United Laboratories International Holdings Limited (HKG:3933) Insiders Sell Shares?
Jan 19We Wouldn't Rely On United Laboratories International Holdings's (HKG:3933) Statutory Earnings As A Guide
Jan 04These 4 Measures Indicate That United Laboratories International Holdings (HKG:3933) Is Using Debt Safely
Dec 20What Type Of Shareholders Own The Most Number of The United Laboratories International Holdings Limited (HKG:3933) Shares?
Dec 07The United Laboratories International Holdings Limited (HKG:3933) Is Yielding 1.3% - But Is It A Buy?
Nov 23Shareholder Returns
| 3933 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | 1.6% | 2.6% | 3.9% |
| 1Y | 15.9% | 1.5% | -7.9% |
Return vs Industry: 3933 exceeded the Hong Kong Pharmaceuticals industry which returned 1.5% over the past year.
Return vs Market: 3933 exceeded the Hong Kong Market which returned -7.9% over the past year.
Price Volatility
| 3933 volatility | |
|---|---|
| 3933 Average Weekly Movement | 7.7% |
| Pharmaceuticals Industry Average Movement | 8.2% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in HK Market | 15.5% |
| 10% least volatile stocks in HK Market | 3.9% |
Stable Share Price: 3933 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: 3933's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 13,600 | n/a | https://www.tul.com.cn |
The United Laboratories International Holdings Limited, an investment holding company, engages in the research, development, manufacture, distribution, and sale of pharmaceutical products. It operates through three segments: Bulk Medicine, Intermediate Products, and Finished Products. The company offers oral antibiotics, antimicrobials for injection, anti-cold products, cough medicines, ophthalmic drugs, antiviral drugs, anti-hepatitis B drugs, diabetes drugs, skin drugs for external use, cardiovascular and cerebrovascular drugs, nervous system drugs, vitamins, and vacant gelatin capsules, as well as API and intermediate products.
The United Laboratories International Holdings Limited Fundamentals Summary
| 3933 fundamental statistics | |
|---|---|
| Market Cap | HK$9.23b |
| Earnings (TTM) | HK$1.15b |
| Revenue (TTM) | HK$11.73b |
8.1x
P/E Ratio0.8x
P/S RatioIs 3933 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3933 income statement (TTM) | |
|---|---|
| Revenue | CN¥10.17b |
| Cost of Revenue | CN¥5.80b |
| Gross Profit | CN¥4.37b |
| Other Expenses | CN¥3.37b |
| Earnings | CN¥994.54m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.55 |
| Gross Margin | 42.98% |
| Net Profit Margin | 9.78% |
| Debt/Equity Ratio | 22.0% |
How did 3933 perform over the long term?
See historical performance and comparison